INTS6L-AS1: A Promising Drug Target / Biomarker (G100874118)

Target Name: INTS6L-AS1

NCBI ID: G100874118

INTS6L-AS1

Other Name(s): DDX26B-AS1 | INTS6L antisense RNA 1

INTS6L-AS1: A Promising Drug Target / Biomarker

INTS6L-AS1 is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the intracellular signaling (ICS) family, which includes proteins that play important roles in regulating cellular signaling pathways. INTS6L-AS1 has been shown to be involved in a number of cellular processes, including cell signaling, cell adhesion, and neurotransmitter release. As a result, INTS6L-AS1 has potential as a drug target or biomarker.

The INTS6L-AS1 protein is composed of 158 amino acid residues and has a calculated molecular mass of 19.9 kDa. It is expressed in a variety of tissues, including the brain, heart, and liver, and is shown to be involved in a number of cellular processes.

One of the key functions of INTS6L-AS1 is its role in cell signaling. INTS6L-AS1 has been shown to be involved in the regulation of several signaling pathways, including the insulin/IGF-1 signaling pathway and the TGF-β signaling pathway. These signaling pathways are important for a variety of cellular processes, including cell growth, differentiation, and survival.

Another function of INTS6L-AS1 is its role in cell adhesion. INTS6L-AS1 is shown to be involved in the regulation of cell adhesion, which is important for the proper functioning of tissues and organs. This is important for processes such as tissue repair and regeneration.

INTS6L-AS1 is also involved in the regulation of neurotransmitter release. This is important for the proper functioning of the nervous system, and is critical for processes such as learning and memory.

Drug Targeting

INTS6L-AS1 is a potential drug target because of its involvement in multiple cellular processes. This makes it an attractive target for small molecule inhibitors, which can be used to treat a variety of diseases.

One approach to targeting INTS6L-AS1 is to use inhibitors of the FAA-ATPase, which is a protein that is involved in the regulation of ATP levels. The FAA-ATPase is a key component of the INTS6L-AS1 signaling pathway, and inhibitors of this protein have been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

Another approach to targeting INTS6L-AS1 is to use inhibitors of the FAK/PI3K signaling pathway, which is involved in the regulation of cell adhesion, angiogenesis, and inflammation. INTS6L-AS1 is shown to be involved in the regulation of this pathway, and inhibitors of this pathway have been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Biomarker

INTS6L-AS1 has the potential to serve as a biomarker for a variety of diseases. For example, INTS6L-AS1 has been shown to be involved in the regulation of cellular signaling pathways, which can be used as a biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

In addition, INTS6L-AS1 has been shown to be involved in the regulation of cell adhesion, which is an important biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Conclusion

INTS6L-AS1 is a protein that is involved in a number of cellular processes, including cell signaling, cell adhesion, and neurotransmitter release. As a result, INTS6L-AS1 has potential as a drug target or biomarker. The use of small molecule inhibitors, such as those that target the FAA-ATPase or the FAK/PI3K signaling pathway, is a promising approach for targeting INTS6L-AS1 and treating a variety of diseases. Additionally, INTS6L-AS1 can serve as a biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

Protein Name: INTS6L Antisense RNA 1

The "INTS6L-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INTS6L-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets